Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

45.30USD
26 Apr 2018
Change (% chg)

-- (--)
Prev Close
$45.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
423,218
52-wk High
$99.45
52-wk Low
$44.84

Latest Key Developments (Source: Significant Developments)

Clovis Oncology Announces Pricing Of Public Offerings Of Convertible Senior Notes And Common Stock
Monday, 16 Apr 2018 08:54pm EDT 

April 16 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES AND COMMON STOCK.CLOVIS ONCOLOGY INC- PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF $300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 1.25% CONVERTIBLE SENIOR NOTES DUE 2025.CLOVIS ONCOLOGY- ANNOUNCED PRICING OF 1.8 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING AT A PRICE TO PUBLIC OF $54.41 PER SHARE.CLOVIS ONCOLOGY INC - PRICED $300 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES AT PRICE TO PUBLIC OF 100% OF PRINCIPAL AMOUNT OF NOTES.  Full Article

Clovis Oncology Files Prospectus Supplement Related To Offering $100 Mln Of Shares Of Co's Common Stock
Monday, 16 Apr 2018 06:45am EDT 

April 16 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $100 MILLION OF SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Clovis Oncology Says Rubraca Approved In U.S. As Maintenance Treatment Of Recurrent Ovarian Cancer
Friday, 6 Apr 2018 01:38pm EDT 

April 6 (Reuters) - Clovis Oncology Inc ::RUBRACA (RUCAPARIB) APPROVED IN THE U.S. AS MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER.U.S. FDA APPROVED RUBRACA TABLETS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CERTAIN TYPES OF RECURRENT CANCER.IN ADDITION TO GRANTING RUBRACA APPROVAL FDA CONVERTED APPROVAL OF INITIAL TREATMENT INDICATION FROM ACCELERATED TO REGULAR APPROVAL.  Full Article

Clovis Oncology reports Q3 adjusted shr loss of $1.24
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Clovis Oncology Inc -:CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS.Q3 ADJUSTED LOSS PER SHARE $1.24 EXCLUDING ITEMS.Q3 LOSS PER SHARE $1.24.Q3 EARNINGS PER SHARE VIEW $-1.22 -- THOMSON REUTERS I/B/E/S.  Full Article

Clovis oncology says entered into a manufacturing services agreement - sec filing
Tuesday, 4 Oct 2016 04:33pm EDT 

Clovis Oncology Inc : Says Clovis Oncology and Lonza Ltd entered into a manufacturing services agreement - SEC filing .Deal provides Lonza will be non-exclusive manufacturer of Rucaparib Api during term of deal , which expires on December 31, 2025.  Full Article

Clovis Oncology announces Rucaparib data presentations at ESMO 2016 Congress
Wednesday, 28 Sep 2016 07:55am EDT 

Clovis Oncology Inc : Clovis Oncology announces Rucaparib data presentations at ESMO 2016 Congress . European Marketing Authorization Application (MAA) planned in Q4 2016 . ESMO will take place october 7-11, 2016 in Copenhagen, Denmark . Prescription Drug User Fee Act (PDUFA) date is February 23, 2017 . U.S. FDA accepted accelerated approval application for review and granted priority review status for Rucaparib .Data from ARIEL3 are expected in Q4 2017, which is expected to be followed by submission of a supplemental NDA.  Full Article

Clovis enters into first amendment to license agreement between Clovis and pfizer
Tuesday, 30 Aug 2016 04:15pm EDT 

Clovis Oncology Inc : Entered into first amendment to license agreement between Clovis and Pfizer, Inc. . First amendment amends existing license agreement, between Clovis and Pfizer, dated June 2, 2011 . Amendment amends license agreement to permit co to defer milestone payments payable upon fda approval of an NDA for 1(st)indication in US .Amendment amends existing license agreement to permit co to defer milestone payments payable on EMA approval of MAA for 1(st)indication in EU.  Full Article

Clovis Oncology says FDA accepts co's new drug application for rucaparib for priority review
Tuesday, 23 Aug 2016 02:30pm EDT 

Clovis Oncology Inc : FDA accepts Clovis Oncology's new drug application for rucaparib for priority review for the treatment of advanced mutant BRCA ovarian cancer .FDA assigns PDUFA date of February 23, 2017.  Full Article

Clovis Oncology Q2 adjusted loss per share $2.07 excluding items
Monday, 8 Aug 2016 04:05pm EDT 

Clovis Oncology Inc : Clovis oncology announces q2 2016 operating results and corporate update . Q2 adjusted loss per share $2.07 excluding items . Q2 earnings per share view $-2.10 -- Thomson Reuters I/B/E/S .Q2 loss per share $3.37.  Full Article

Clovis Oncology Inc files for mixed shelf of up to $200 mln
Friday, 10 Jun 2016 06:21am EDT 

Clovis Oncology Inc :Clovis Oncology Inc files for mixed shelf of up to $200 million.  Full Article

BRIEF-Clovis Oncology Announces Pricing Of Public Offerings Of Convertible Senior Notes And Common Stock

* CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES AND COMMON STOCK